We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Protein in Snake Venom Stops Bleeding

By HospiMedica staff writers
Posted on 31 Mar 2006
A blood-clotting protein found in snake venom could rapidly stop excessive bleeding during vascular surgery and major trauma. More...


The protein responsible for the pro-coagulant or blood-clotting effect in the venom was found in the deadly coastal taipan snake and is called factor X. Factor X can stem blood flow in a matter of seconds. Mammals and snakes naturally produce a small amount of factor X in their livers, but snakes produce a more stable and faster acting form of the factor in their venom, which is the only source of factor X other than mammalian livers.

An experimental drug based on factor X is being evaluated for clinical trials by biopharmaceutical-development company QRxPharma (Toowong, Australia). Australia has 17 of the world's most deadly snakes, many of which have not been studied for therapeutic leads.

The protein was identified by Ph.D. researcher Liam St. Pierre, from the Queensland University of Technology School of Life Sciences (Brisbane, QLD, Australia), who studied the venom of eight of Australia's deadliest land snakes for their therapeutic potential.

Australian snakes literally have a two-pronged attack when they bite their prey. Firstly, venom injection causes massive blood clots instantaneously followed by paralysis as a result of neurotoxins which eventually immobilize and kill the victim,” said Dr. St. Pierre. They have developed the ability to deliver massive fatal doses of factor X to specifically target the systems of mammals.



Related Links:
Queensland University of Technology

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.